CORONAVIRUS | News
https://www.ctvnews.ca/health/...
European regulator could OK 1st COVID-19 vaccine on Dec. 29
Frank Jordans, Maria Cheng and Samuel Petrequin
The Associated Press Staff
Contact
Published Tuesday, December 1, 2020 7:16AM EST Last Updated Tuesday, December 1, 2020 10:16AM EST
BioNTech vaccine developed with Pfizer
BioNTech chief executive says the vaccine developed with Pfizer may start delivery in December. (AFP)
BERLIN -- European regulators may approve a coronavirus vaccine developed by drugmakers Pfizer and BioNTech within four weeks, the EU's drug agency said Tuesday, a time frame that could mean the shot is rolled out first in the United States and Britain.

The European Medicines Agency plans to convene a meeting by Dec. 29 to decide if there is enough safety and efficacy data about the vaccine for it to be approved, the regulator said. The agency also said it could decide as early as Jan. 12 whether to approve a rival vaccine shot by Moderna Inc.

German pharmaceutical company BioNTech and its U.S. partner Pfizer said earlier Tuesday that they had asked the European regulator for expedited approval of their vaccine. The companies have said that clinical trials showed the vaccine is 95% effective.
CTV News COVID-19 Coverage

Full coverage at CTVNews.ca/Coronavirus

Tracking every case of COVID-19 in Canada

Public health must balance science and society: former top doctor

Scientists find new clues, but origin of COVID-19 still a mystery

Ontario records more than 1,700 new cases of COVID-19 for third straight day as testing slumps

Federal deficit on track to exceed $381B, as spending increases in wake of second COVID-19 wave

Canadians offer mixed confidence in government's vaccine rollout: Nanos survey

Study looks at how COVID-19 invades the brain in severe cases

The COVID-19 'long-haulers' behind a global patient movement

Virtual celebrations and outdoor parties: How the office Christmas party will be different this year

European regulator could OK 1st COVID-19 vaccine on Dec. 29

Ontario parents can now apply for second COVID-19 payout. Here's how

Calgary's South Asian community demands premier apologize after 'wake up call' comments

Oregon nurse put on administrative leave after posting TikTok bragging about breaking COVID-19 rules

Doctor embraces elderly COVID-19 patient in heartbreaking photo from Texas
Related Stories

Moderna asking U.S., European regulators to OK its COVID-19 shots
Canada's first vaccine approval could come before Christmas, chief health adviser says
Europe was largest contributor to new COVID-19 cases and deaths in the past week, WHO says

Newsletter sign-up: Get The COVID-19 Brief sent to your inbox

Multiple successful vaccines will be needed to end the pandemic, which has been on the upswing in Europe and the U.S. and so far left more than 1.4 million people worldwide dead. Pfizer and BioNTech have already sought approval to begin vaccinations in the U.S. in December. Rival Moderna said Monday it was asking U.S. and European regulators to allow the use of its vaccine.

British regulators also are assessing the Pfizer shot and another from AstraZeneca. There are several other vaccines in development, including in Russia and China.

Even after vaccines are approved, manufacturers and regulators will be monitoring how well they are received by patients to determine the frequency of rarer side effects that may only appear when millions are immunized. While the vaccines so far submitted for approval seem to prevent people from getting sick, it is still unclear whether they prevent people from picking up the virus entirely -- and crucially -- passing it to others.

And officials caution that while some people may receive a vaccine in the coming weeks, it will take many months to give billions of people around the world the shot, or two if a booster is necessary, meaning that people will be living with virus control measures well into next year.

If its vaccine is approved, BioNTech said its use in Europe could begin before the end of 2020 -- tough but not impossible if approval comes Dec. 29. The regulator has also left open the possibility that the date of that meeting will be moved up if data comes in faster.

The Dec. 29 date would be later than some European countries had hoped for. Germany, which has given BioNTech 375 million euros (US$451 million) in funding to develop the vaccine, has been preparing to start immunizing people from mid-December onward.

Since requests have already been made to U.S. and U.K. regulators, approval might come from them first -- and authorities the world over are promising to work with drugmakers to roll out the first shots within days, if not hours, of approval.

Vaccine tracker: The top contenders to stop the novel coronavirus

"We have known since the beginning of this journey that patients are waiting, and we stand ready to ship COVID-19 vaccine doses as soon as potential authorizations will allow us," Pfizer's chief executive Albert Bourla said in a statement.

BioNTech said it stands ready to ship stockpiles of vaccines where they are needed when the Amsterdam-based European agency or the U.S. Food and Drug Administration approve the vaccine.

"Depending on how the authorities decide we can start delivering within a few hours," said BioNTech's chief operating officer, Sierk Poetting.

The European Union's top official said Tuesday around 2 billion doses of potential COVID-19 vaccines have been secured for the bloc's 27 nations, with the first deliveries likely to start before the end of the year.

EU Commission President Ursula von der Leyen said member-states have started working on their vaccination plans and on the logistics for delivering tens of millions of doses across the bloc.

"It will be a huge step forward toward our normal life," Von der Leyen said. "In other words, I just wanted to say there is a light at the end of the tunnel."

Von der Leyen, however, urged EU citizens to remain "disciplined till we have reached finally a vaccination that is appropriate to eradicate this virus." As infections and hospitalizations surged in Europe in recent weeks, many countries tightened their restrictions. Some of those measures are beginning to have an effect, but many remain worried that family gatherings at Christmas could lead to a new surge.

Amid concerns about the safety of the vaccines given the tremendous speed with which they have been developed, Germany's science minister said Tuesday that the same safety standards are being applied in the approval process for coronavirus vaccines as for other drugs.

Anja Karliczek said that maintaining the highest standards is key to gaining the widest possible public acceptance for coronavirus immunization.

Speaking to reporters in Berlin, Karliczek stressed that the vaccine will be voluntary and that authorities will work hard to inform the public about possible side effects that a small percentage of recipients might experience after immunization, such as headaches, exhaustion and fever. The EMA plans to hold a public meeting on Dec. 11 to explain how COVID-19 vaccines are regulated to ensure they work and are safe.

Marylyn Addo, a doctor at Hamburg's UKE hospital who is involved in the trials for a rival vaccine, said the speed of coronavirus vaccine development was the result of enormous efforts by scientists, early funding and experience from previous vaccines.

------

Cheng reported from London and Petrequin from Brussels
Correction:

This story has been updated to correct that Pfizer and BioNTech asked for expedited approval of their vaccine, not an emergency use authorization.

Märkmed: